Free Trial
→ Elon Takes Aim at Social Security (From Altimetry) (Ad)

PepGen Q2 2023 Earnings Report

PepGen logo
$1.37 -0.07 (-4.86%)
As of 02/21/2025 04:00 PM Eastern
Earnings HistoryForecast

PepGen EPS Results

Actual EPS
-$0.82
Consensus EPS
-$0.81
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

PepGen Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PepGen Announcement Details

Quarter
Q2 2023
Date
8/8/2023
Time
N/A

Conference Call Resources

PepGen Earnings Headlines

PepGen stock plunges to 52-week low at $1.16 amid market challenges
February 13, 2025 | msn.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
February 4, 2025 | prnewswire.com
$5,000 DOGE check?
Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a portion of the savings DOGE makes in Federal cuts could be funneled back to taxpayers. The media was quick to dub it a DOGE Dividend, with claims circulating that we could all receive a $5,000 check in the mail.
February 23, 2025 | Altimetry (Ad)
PepGen announces CONNECT program updates
January 31, 2025 | markets.businessinsider.com
H.C. Wainwright cuts PepGen stock target to $16, maintains Buy rating
January 31, 2025 | msn.com
Cautiously Optimistic Buy Rating for PepGen Inc. Amid Safety Concerns and Positive Pipeline Progress
January 31, 2025 | markets.businessinsider.com
See More PepGen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PepGen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PepGen and other key companies, straight to your email.

About PepGen

PepGen (NASDAQ:PEPG), a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

View PepGen Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles